Skip to main content
Erschienen in: Intensive Care Medicine 5/2006

01.05.2006 | Brief Report

Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia

verfasst von: Olivier Mimoz, Delphine Rolland, Michèle Adoun, Sandrine Marchand, Dominique Breilh, Ivan Brumpt, Bertrand Debaene, William Couet

Erschienen in: Intensive Care Medicine | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the steady-state trough serum and epithelial lining fluid (ELF) concentrations of teicoplanin 12 mg/kg per day in critically ill patients with ventilator associated pneumonia.

Design and setting

Prospective, pharmacokinetic study in the surgical intensive care unit in a university hospital.

Patients

Thirteen adult patients with nosocomial bacterial pneumonia on mechanical ventilation were enrolled.

Interventions

All subjects received a 30-min intravenous infusion of 12 mg/kg teicoplanin every 12 h for 2 consecutive days followed by 12 mg/kg once daily. Teicoplanin concentrations in serum and ELF were determined simultaneously 4–6 days after antibiotic administration started.

Measurements and results

The median total and free concentrations of teicoplanin in serum at trough were 15.9 μg/ml (range 8.8–29.9) and 3.7 (2.0–5.4), respectively. The concentration in ELF was 4.9 (2.0–11.8).

Conclusions

In critically ill patients with ventilator-associated pneumonia the administration of high teicoplanin doses is required to reach sufficient trough antibiotic concentrations in lung tissues at steady state. At that time trough-free concentrations of teicoplanin in serum and ELF are comparable.
Literatur
1.
2.
Zurück zum Zitat Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ (1993) Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 37:1065–1072PubMed Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ (1993) Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 37:1065–1072PubMed
3.
Zurück zum Zitat Wilson APR (2000) Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 39:167–173PubMedCrossRef Wilson APR (2000) Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 39:167–173PubMedCrossRef
4.
Zurück zum Zitat Moreo G, Sardi C, Volpato G, Romeo B, Cavenaghi L (1989) Penetration of teicoplanin into bronchial secretion and respiratory tract tissues. Eur Respir J 2 [Suppl 8]:733S Moreo G, Sardi C, Volpato G, Romeo B, Cavenaghi L (1989) Penetration of teicoplanin into bronchial secretion and respiratory tract tissues. Eur Respir J 2 [Suppl 8]:733S
5.
Zurück zum Zitat Baldwin DR, honeybourne D, Wise R (1992) Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 36:1171–1175PubMed Baldwin DR, honeybourne D, Wise R (1992) Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 36:1171–1175PubMed
6.
Zurück zum Zitat Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28:143–160PubMedCrossRef Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28:143–160PubMedCrossRef
7.
Zurück zum Zitat MacGowan AP (1998) Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 20:473–477PubMedCrossRef MacGowan AP (1998) Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 20:473–477PubMedCrossRef
8.
Zurück zum Zitat Menichetti F (2005) Current and emerging serious Gram positive infections. Clin Microbiol Infect 11 [Suppl 3]:22–28 Menichetti F (2005) Current and emerging serious Gram positive infections. Clin Microbiol Infect 11 [Suppl 3]:22–28
9.
Zurück zum Zitat Wilson APR, Gruneberg RN, Neu H (1994) A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 4 [Suppl 1]:1–30 Wilson APR, Gruneberg RN, Neu H (1994) A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 4 [Suppl 1]:1–30
10.
Zurück zum Zitat Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM (1995) Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 39:1842–1847PubMed Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM (1995) Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 39:1842–1847PubMed
11.
Zurück zum Zitat Liu P, Mueller M, Derendorf H (2002) Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19:285–290PubMedCrossRef Liu P, Mueller M, Derendorf H (2002) Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19:285–290PubMedCrossRef
12.
Zurück zum Zitat Pham LH, Brun-Buisson C, Legrand P, Rauss A, Verra F, Brochard L, Lemaire F (1991) Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am Rev Respir Dis 143:1055–1061PubMed Pham LH, Brun-Buisson C, Legrand P, Rauss A, Verra F, Brochard L, Lemaire F (1991) Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am Rev Respir Dis 143:1055–1061PubMed
13.
Zurück zum Zitat Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
14.
Zurück zum Zitat Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmele T, Chassard D, Saux MC, Allaouchiche B (2004) Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:976–979PubMedCrossRef Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmele T, Chassard D, Saux MC, Allaouchiche B (2004) Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:976–979PubMedCrossRef
15.
Zurück zum Zitat Boselli E, Breilh D, Rimmele T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B (2004) Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:989–991PubMedCrossRef Boselli E, Breilh D, Rimmele T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B (2004) Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:989–991PubMedCrossRef
16.
Zurück zum Zitat Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B (2003) Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 31:2102–2106PubMedCrossRef Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B (2003) Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 31:2102–2106PubMedCrossRef
17.
Zurück zum Zitat Boselli E, Breilh D, Rimmele T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B (2005) Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 33:1529–1533PubMedCrossRef Boselli E, Breilh D, Rimmele T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B (2005) Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 33:1529–1533PubMedCrossRef
18.
Zurück zum Zitat Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, Farinotti R, Chastre J, Gibert C (1993) Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37:281–286PubMed Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, Farinotti R, Chastre J, Gibert C (1993) Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37:281–286PubMed
19.
Zurück zum Zitat Conte JE Jr, Golden JA, Kipps J, Zurlinden E (2002) Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46:1475–1480PubMedCrossRef Conte JE Jr, Golden JA, Kipps J, Zurlinden E (2002) Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46:1475–1480PubMedCrossRef
20.
Zurück zum Zitat Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R (2003) Intrapulmonary penetration of linezolid. J Antimicrob Chemother 51:1431–1434PubMedCrossRef Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R (2003) Intrapulmonary penetration of linezolid. J Antimicrob Chemother 51:1431–1434PubMedCrossRef
21.
Zurück zum Zitat Harding I, MacGowan AP, White LO, Darsley ERS, Reed V (2000) Teicoplanin therapy for Staphylococcus aureus septicemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 45:835–841 PubMedCrossRef Harding I, MacGowan AP, White LO, Darsley ERS, Reed V (2000) Teicoplanin therapy for Staphylococcus aureus septicemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 45:835–841 PubMedCrossRef
Metadaten
Titel
Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia
verfasst von
Olivier Mimoz
Delphine Rolland
Michèle Adoun
Sandrine Marchand
Dominique Breilh
Ivan Brumpt
Bertrand Debaene
William Couet
Publikationsdatum
01.05.2006
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 5/2006
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-006-0136-3

Weitere Artikel der Ausgabe 5/2006

Intensive Care Medicine 5/2006 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.